Cyclin D1 Overexpression in Breast Carcinoma and Its Correlation with Standard Clinicopathological Parameters

Jasmine; Ajay Kumar Kochhar; Aditi Baghla; Karandeep Singh

doi:10.21276/apalm.3710

Authors

Jasmine Department of Pathology, Maharaja Agrasen Medical College, Agroha, Haryana, India.
Ajay Kumar Kochhar Department of Pathology, Maharaja Agrasen Medical College, Agroha, Haryana, India.
Aditi Baghla Department of Pathology, Maharaja Agrasen Medical College, Agroha, Haryana, India.
Karandeep Singh Department of Pathology, Maharaja Agrasen Medical College, Agroha, Haryana, India.

DOI:

https://doi.org/10.21276/apalm.3710

Keywords:

breast cancer, cyclin d1, estrogen receptor, immunohistochemistry, progesterone receptor

Abstract

Background: Breast cancer remains the most frequently diagnosed malignancy among women worldwide, with a significant disease burden in India where incidence is rising at younger ages. Conventional prognostic and predictive markers, including ER, PR, and HER2, play a central role in guiding management, yet outcomes remain variable. Cyclin D1, a cell cycle regulatory protein encoded by CCND1, is increasingly recognized as a potential biomarker in breast cancer due to its role in cell cycle control and interaction with hormone receptor pathways. Evaluating Cyclin D1 expression and its association with established prognostic markers may provide valuable insights into disease behavior and therapeutic response.

Materials and Methods: This study was carried out on 40 histologically confirmed cases of breast carcinoma. Expression of Cyclin D1, ER, PR, and HER2/neu was assessed using standard IHC protocols and scored according to ASCO/CAP guidelines. Statistical analysis was performed, with p < 0.05 considered significant.

Results: Cyclin D1 expression was detected in 23 (57.5%) out of 40 cases. Cyclin D1 expression showed a significant positive correlation with ER (p < 0.001) and PR (p < 0.001) status, but not with HER2/neu. Significant association was also observed between Cyclin D1 and molecular subtypes (p < 0.001), with positivity in all Luminal A and Luminal B cases, and negative correlation with TNBC.

Conclusion: Cyclin D1 expression was significantly associated with ER, PR, and Luminal A/B subtypes, but not with HER2, age, or nodal status, and showed negative correlation with TNBC. These findings suggest Cyclin D1 as a potential biomarker in hormone receptor–positive breast cancers, meriting validation in larger studies.

References

1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May-Jun;74(3):229-63.

2. Mehrotra R, Yadav K. Breast cancer in India: Present scenario and the challenges ahead. World J Clin Oncol. 2022 Mar 3;13(3):209-18.

3. Abdelnaby AA, Azzam EA. Immunohistochemical Expression of Cyclin D1 in Breast Carcinoma. Egypt J Hosp Med. 2022 Apr 1;87(1):2082-90.

4. Mohammadizadeh F, Hani M, Ranaee M, Bagheri M. Role of cyclin D1 in breast carcinoma. J Res Med Sci. 2013 Dec;18(12):1021.

5. Siraj AK, Parvathareddy SK, Annaiyappanaidu P, Ahmed SO, Siraj N, Tulbah A et al. High Expression of Cyclin D1 is an Independent Marker for Favourable Prognosis in Middle Eastern Breast Cancer. Onco Targets Ther. 2021 May 19;14:3309-18.

6. Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer. 2011 Aug;11(8):558-72.

7. Montalto FI, De Amicis F. Cyclin D1 in cancer: a molecular connection for cell cycle control, adhesion and invasion in tumour and stroma. Cells. 2020 Dec 9;9(12):2648.

8. Hammond M, Hayes D, Dowsett M, Allred D, Hagerty K, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version) Arch Pathol Lab Med. 2010;134(7):48–72.

9. Wolff A, Hammond M, Hicks D, Dowsett M, McShane L, Allison K, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. Arch Pathol Lab Med. 2014;138(2):241–56.

10. Ravikumar G, Ananthamurthy A. Cyclin D1 expression in ductal carcinoma of the breast and its correlation with other prognostic parameters. J Cancer Res Ther. 2014 Jul 1;10(3):671-5.

11. Mehta R, Yadav R. Carcinoma Breast: Correlation of Immunohistohemical Expression of Cyclin D1 and Its Correlation with Clinicopathological Parameters in Indian Patients at Tertiary Care Hospital. Int J Oncol Res 2022 Aug 29; 5:044.

12. Lamb R, Lehn S, Rogerson L, Clarke RB, Landberg G. Cell cycle regulators cyclin D1 and CDK4/6 have estrogen receptor-dependent divergent functions in breast cancer migration and stem cell-like activity. Cell Cycle. 2013 Aug 1;12(15):2384-94.

13. Sarkar S, Kanoi A, Bain J, Gayen R, Das KN. Correlation between cyclin D1 expression and standard clinicopathological variables in invasive breast cancer in Eastern India. South Asian J Cancer. 2015 Oct;4(04):155-9.

14. Parvin T, Das C, Choudhury M, Chattopadhyay BK, Mukhopadhyay M. Prognostic utility of cyclin D1 in invasive breast carcinoma. Indian J Surg Oncol. 2019 Mar 6;10:167-73.

15. Li Z, Cui J, Yu Q, Wu X, Pan A, Li L. Evaluation of CCND1 amplification and CyclinD1 expression: diffuse and strong staining of CyclinD1 could have same predictive roles as CCND1 amplification in ER positive breast cancers. Am J Transl Res. 2016 Jan 15;8(1):142-53.

16. Guo L, Liu S, Jakulin A, Yilamu D, Wang B, Yan J. Positive expression of cyclin D1 is an indicator for the evaluation of the prognosis of breast cancer. Int J Clin Exp Med. 2015 Oct 15;8(10):18656-64.